PriceTargets.com logo

Arix Bioscience - ARIX Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: GBX 0
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
GBX 142 As of 02/12/2024 10:20 PM ET
+0 (0.00%)

This chart shows the closing price for ARIX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Arix Bioscience Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ARIX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ARIX

Analyst Price Target is GBX 0
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Arix Bioscience in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a -100.00% upside from the last price of GBX 142.

This chart shows the closing price for ARIX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Arix Bioscience. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/24/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/22/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/19/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/12/2021Shore CapitalReiterated RatingHold
7/6/2021Peel HuntReiterated RatingBuyGBX 256
7/6/2021Peel HuntReiterated RatingBuyGBX 256
4/26/2021Shore CapitalReiterated RatingHold
3/10/2021Shore CapitalReiterated RatingBuy
1/18/2021Shore CapitalReiterated RatingBuy
4/6/2020Shore CapitalReiterated RatingUnder Review
10/23/2019Shore CapitalInitiated CoverageBuy
(Data available from 4/19/2019 forward)

News Sentiment Rating

0.27 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2023
  • 1 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2023
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/20/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/19/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/20/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/19/2024

Current Sentiment

  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Arix Bioscience logo
Arix Bioscience plc is a venture capital firm specializing in all stages of growth, seed stage, preclinical and clinical stage assets, startup, early stage, mid venture, late stage, growth capital investments as well as private and public equity. The firm seeks to invest in biotech companies, novel therapeutics, innovative technologies, medical innovation comprising healthcare and life sciences. It seeks to invest globally. The firm employs an evergreen approach to funding. It primarily makes investments from its own balance sheet. The firm prefers to take board seat. The firm exit when the optimum value has been reached. Arix Bioscience plc is formerly known as Perceptive Bioscience Investments Limited. Arix Bioscience plc was founded in 2015 and is based in London, United Kingdom.
Read More

Today's Range

Now: GBX 142
Low: 142
High: 142

50 Day Range

MA: GBX 142.12
Low: 142
High: 144.50

52 Week Range

Now: GBX 142
Low: 97
High: 145

Volume

377,046 shs

Average Volume

636,934 shs

Market Capitalization

£183.73 million

P/E Ratio

1,290.91

Dividend Yield

N/A

Beta

1.05

Frequently Asked Questions

What sell-side analysts currently cover shares of Arix Bioscience?

The following Wall Street sell-side analysts have issued reports on Arix Bioscience in the last year:
View the latest analyst ratings for ARIX.

What is the current price target for Arix Bioscience?

0 Wall Street analysts have set twelve-month price targets for Arix Bioscience in the last year. has the lowest price target set, forecasting a price of £100,000 for Arix Bioscience in the next year.
View the latest price targets for ARIX.

What is the current consensus analyst rating for Arix Bioscience?

Arix Bioscience currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for ARIX.

What other companies compete with Arix Bioscience?

Other companies that are similar to Arix Bioscience include hVIVO, Avacta Group, Oxford Biomedica, Circassia Group and Verona Pharma plc (VRP.L). Learn More about companies similar to Arix Bioscience.

How do I contact Arix Bioscience's investor relations team?

Arix Bioscience's physical mailing address is 20 Berkeley Square, LONDON, W1J 6EQ, United Kingdom. The company's listed phone number is +44-20-72901050. The official website for Arix Bioscience is arixbioscience.com. Learn More about contacing Arix Bioscience investor relations.